[go: up one dir, main page]

SG10201709955PA - Methods of treatment and compositions with xanthine oxidase inhibitors - Google Patents

Methods of treatment and compositions with xanthine oxidase inhibitors

Info

Publication number
SG10201709955PA
SG10201709955PA SG10201709955PA SG10201709955PA SG10201709955PA SG 10201709955P A SG10201709955P A SG 10201709955PA SG 10201709955P A SG10201709955P A SG 10201709955PA SG 10201709955P A SG10201709955P A SG 10201709955PA SG 10201709955P A SG10201709955P A SG 10201709955PA
Authority
SG
Singapore
Prior art keywords
compositions
treatment
methods
xanthine oxidase
oxidase inhibitors
Prior art date
Application number
SG10201709955PA
Inventor
Lhanoo Gunawardhana
Vijay Gupte
Himanshu Naik
Michael Mayer
Kanji Komatsu
Original Assignee
Takeda Pharmaceuticals Usa Inc
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Usa Inc, Teijin Pharma Ltd filed Critical Takeda Pharmaceuticals Usa Inc
Publication of SG10201709955PA publication Critical patent/SG10201709955PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201709955PA 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors SG10201709955PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361829759P 2013-05-31 2013-05-31
US201361839609P 2013-06-26 2013-06-26

Publications (1)

Publication Number Publication Date
SG10201709955PA true SG10201709955PA (en) 2018-01-30

Family

ID=50983231

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201709955PA SG10201709955PA (en) 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors
SG11201509738RA SG11201509738RA (en) 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201509738RA SG11201509738RA (en) 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors

Country Status (9)

Country Link
US (2) US20140357683A1 (en)
JP (2) JP2016520133A (en)
CN (1) CN105579037A (en)
CA (1) CA2913755A1 (en)
MX (1) MX2015016494A (en)
PH (1) PH12015502679A1 (en)
SG (2) SG10201709955PA (en)
TW (1) TW201536284A (en)
WO (1) WO2014194226A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018005345A (en) * 2015-10-28 2018-08-14 Sun Pharmaceutical Ind Ltd Pharmaceutical compositions of dimethyl fumarate.
CN105769766B (en) * 2016-03-24 2018-07-06 长沙佰顺生物科技有限公司 A kind of Topiroxostat nano-emulsion and preparation method thereof
JP7108384B2 (en) * 2016-07-13 2022-07-28 日本ケミファ株式会社 Orally disintegrating tablet of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid
EP3484862B1 (en) * 2016-07-18 2021-09-01 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
JP2022511800A (en) 2018-12-06 2022-02-01 アースローシ セラピューティクス，インク． Crystalline form of compound for treating or preventing gout or hyperuricemia
US20220323441A1 (en) * 2019-06-04 2022-10-13 Nippon Chemiphar Co., Ltd. Therapeutic for gout or hyperuricemia
EP4360631A4 (en) * 2021-06-15 2025-05-21 Lg Chem, Ltd. PHARMACEUTICAL COMPOSITION COMPRISING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID
CN115252567A (en) * 2022-07-08 2022-11-01 广西纯正堂制药有限公司 Febuxostat osmotic pump sustained-release tablet and preparation method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5544163A (en) 1994-03-08 1996-08-06 Excel, Inc. Expandable telecommunications system
AU2003220909B2 (en) 2002-03-28 2008-09-18 Teijin Limited Solid preparation containing single crystal form
WO2005121153A1 (en) * 2004-06-14 2005-12-22 Nippon Chemiphar Co., Ltd. Condensed pyrimidine derivative and xanthine oxidase inhibitor
CA2621038A1 (en) 2005-10-07 2007-04-19 Astellas Pharma Inc. Triarylcarboxylic acid derivative
BRPI0806608A2 (en) * 2007-01-19 2011-09-06 Takeda Pharmaceuticals North America Inc methods to prevent or reduce the number of acute gout outbreaks using xanthine oxidoreductase inhibitors and anti-inflammatory agents
DK2415771T3 (en) 2009-03-31 2013-10-14 Kissei Pharmaceutical Indolizine derivative and its use for medical purposes
CN101773498B (en) * 2009-12-30 2012-06-20 青岛黄海制药有限责任公司 Preparation method of oral slow/controlled-release preparation containing febuxostat
CN103210084B (en) * 2010-06-16 2016-04-20 武田制药美国有限公司 The release dosage form of the new improvement of xanthine oxidoreductase inhibitors or xanthine oxidase inhibitor
MX339452B (en) 2010-06-16 2016-05-27 Teijin Pharma Ltd Controlled release nucleated tablet.
CN102641255A (en) * 2012-05-08 2012-08-22 南方医科大学 Febuxostat osmotic pump controlled release tablet for treating gout and preparation method

Also Published As

Publication number Publication date
SG11201509738RA (en) 2015-12-30
TW201536284A (en) 2015-10-01
JP2019108356A (en) 2019-07-04
US20180311217A1 (en) 2018-11-01
CN105579037A (en) 2016-05-11
WO2014194226A2 (en) 2014-12-04
CA2913755A1 (en) 2014-12-04
WO2014194226A3 (en) 2015-05-14
JP2016520133A (en) 2016-07-11
MX2015016494A (en) 2016-11-18
US20140357683A1 (en) 2014-12-04
PH12015502679A1 (en) 2016-03-07

Similar Documents

Publication Publication Date Title
IL255269A (en) Compositions of obeticholic acid and methods of use
IL259801A (en) Inhibitors of ezh2 and methods of use thereof
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
GB201320723D0 (en) Composition and methods of treatment
PL3240785T3 (en) Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
ZA201601701B (en) Inhibitors of erk and methods of use
SG11201504022RA (en) Glutamase inhibitors and method of use
EP3016652A4 (en) Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors
SG11201509738RA (en) Methods of treatment and compositions with xanthine oxidase inhibitors
IL243728A0 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
PT3021839T (en) Methods and compositions for treatment of fibrosis
IL240695A0 (en) Nme inhibitors and methods of using nme inhibitors
PL3082845T3 (en) Methods and compositions for treatment of peripheral neuropathies
PL2968478T3 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
IL245123A0 (en) Sirna and their use in methods and compositions for inhibiting the expression of the orai1 gene
SG11201603506PA (en) Treatment of damaged nerve with pten inhibitor
EP3102567A4 (en) Inhibitors of paxillin function and related compositions and methods
EP3068431A4 (en) Methods and compositions for the treatment of hcmv
GB201312311D0 (en) Uses of enzyme inhibitors
PT3083848T (en) Composition and method for wood or derivatives of wood
GB201310349D0 (en) Composition and method of use thereof
GB201301928D0 (en) Composition and method of use thereof
GB201409466D0 (en) Urea compounds and their use as enzyme inhibitors